Schizophrenia Mental and Behavioural Disorders Schizophrenia
Conditions
Interventions
Patients will be randomised to either the ziprasidone or clozapine group. After 3, 6 and 12 months, we evaluate the possible effects on the course of schizophrenia and the consumption of cannabis. Mor
Sponsors
University of Cologne (Germany)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients with schizophrenia, schizophreniform or schizoaffective disorder according to Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) (295.xx) and International Statistical Classification of Diseases and Related Health Problems - tenth revision (ICD-10) (F20, F23.2, F25) as well as cannabis abuse or dependence according to DSM-IV (305.20, 304.30) and ICD-10 (F12.1, 12.2) 2. Capable of giving written informed consent
Exclusion criteria
Exclusion criteria: 1. Other relevant neuropsychiatric disorders 2. Prominent (acute) positive symptoms at the timepoint of inclusion 3. Previous treatments with ziprasidone or clozapine with significant side effects 4. No availability of a family member or significant other for the collateral interviews of the follow-up evaluation 5. No compliance with the requirements of the study/lack of or questionable capability of giving informed consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Amount of cannabis consumption 12 months after inclusion in the study 2. Less side effects in ziprasidone group 3. After 12 months: 3.1. Better compliance in ziprasidone group 3.2. Better course of schizophrenia within the ziprasidone group | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Amount of cannabis consumption 3 and 6 months after inclusion in the study 2. Others compared with primary outcomes just to 3 and 6 months | — |
Countries
Germany
Outcome results
None listed